Market Snapshot

BSE Sensex: 77054.94 -0.72%
BSE 500: 36265.57 -0.67%
BSE 200: 11261.25 -0.63%
BSE 100: 25611.75 -0.72%
BSE BANKEX: 65020.86 -1.16%
BSE IT: 27855.02 -1.09%
Nifty 50: 24052.05 -0.66%
Nifty 500: 23199.45 -0.63%
Nifty 200: 13923.4 -0.57%
Nifty 100: 25088.65 -0.60%
Nifty Midcap 100: 62766.4 -0.44%
Nifty Small 100: 19227.35 -1.01%
Nifty IT: 28724.75 -1.00%
Nifty PSU Bank: 8307.9 -1.80%

News:

Krishana Phoschem slips as Q1 ...
Volumes jump at Nuvoco Vistas ...
Landmark Cars soars after reve...
Nuvoco Vistas Corp spurts afte...
National Aluminium Company Ltd...

Sakar Healthcare Ltd Share Price – NSE
Pharmaceuticals, Small Cap

Invest

14 Jul 2026 | 03:31 PM

904.45

40.95 (4.74%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

164.42%

Return (1Y)

Beaten Nifty 50 by 167.89%
More Volatile

3.19%

Standard Deviation (1Y)

Higher than Nifty 50 by 2.36%
Consistent Performer

7/12

Months

beaten Nifty 50
AxisDirect View

No View

52 Week High-Low

890

311

News & Announcements

Sakar Healthcare jumps after Gautam Baid-founded fund buys stake via bulk deal
57 days ago

Sakar Healthcare jumps after Gautam Baid-founded fund buys stake via bulk deal

18 - May - 2026 12:00 | 57 days ago

According to the bulk deal data on the NSE , Stellar Wealth Partners India Fund I LP purchased 1.95 lakh shares, representing a 0.88% equity stake, at an average price of Rs 664.58 per share.
Gautam Baid or Stellar Wealth Partners India Fund I LP did not feature in Sakar Healthcare?s shareholding pattern for the quarter ended 31 March 2026. This suggests a fresh stake entry in the current quarter.
Stellar Wealth Partners India Fund I LP is a Delaware-based investment partnership founded by investor Gautam Baid.
Ahmedabad-based Sakar Healthcare is a pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products.
On a consolidated basis, Sakar Healthcare's net profit surged 91.32% to Rs 11.02 crore while net sales rose 41.52% to Rs 71.10 crore in Q4 March 2026 over Q4 March 2025.

Powered by Capital Market - Live News

Sakar Healthcare consolidated net profit rises 91.32% in the March 2026 quarter

63 days ago

Sakar Healthcare to hold board meeting
68 days ago

Sakar Healthcare to hold board meeting

07 - May - 2026 12:00 | 68 days ago

Sakar Healthcare will hold a meeting of the Board of Directors of the Company on 12 May 2026.
Sakar Healthcare consolidated net profit rises 126.27% in the December 2025 quarter
159 days ago

Sakar Healthcare consolidated net profit rises 126.27% in the December 2025 quarter

05 - Feb - 2026 12:00 | 159 days ago

Net profit of Sakar Healthcare rose 126.27% to Rs 10.25 crore in the quarter ended December 2025 as against Rs 4.53 crore during the previous quarter ended December 2024. Sales rose 62.00% to Rs 70.34 crore in the quarter ended December 2025 as against Rs 43.42 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 70.34 43.42 62

OPM % 26.43 27.06 -

PBDT 17.33 10.76 61

PBT 10.95 5.53 98

NP 10.25 4.53 126

Powered by Capital Market - Live News

Price vs Volume

1D
5D
1M
3M
1Y
3Y
5Y
MAX

Stock Trivia

Sakar Healthcare Ltd is trading very close to its All time High
Sakar Healthcare Ltd is trading very close to its 52 Week High
FII shareholding in Sakar Healthcare Ltd has decreased by -4.86% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

×

Online trading for clients based in USA and Canada is restricted. You can continue placing orders through mapped dealers offline

OK

vV5.0.0.6-60